Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4009597 | 0.96 | EPHX2 (0.67) | EPHX2 | |
| SCHEMBL4010983 | 0.95 | EPHX2 (0.69) | EPHX2 | |
| SCHEMBL4010714 | 0.95 | EPHX2 (0.69) | EPHX2 | |
| SCHEMBL3226878 | 0.95 | EPHX2 (0.69) | EPHX2 | |
| SCHEMBL4014039 | 0.85 | EPHX2 (0.66) | EPHX2HTT | |
| SCHEMBL4012695 | 0.82 | EPHX2 (0.69) | EPHX2HTT | |
| SCHEMBL4012087 | 0.82 | EPHX2 (0.69) | EPHX2 | |
| SCHEMBL4010076 | 0.82 | EPHX2 (0.70) | EPHX2 | |
| SCHEMBL4012368 | 0.80 | EPHX2 (0.69) | EPHX2HTT | |
| SCHEMBL4016422 | 0.80 | EPHX2 (0.70) | EPHX2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063583-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ARETE THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | EPHX1, ECE1, LIPG | EPHX2 5/4885HTT 4428/4885 |
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | EPHX1, PTGIS, PDE3A | EPHX2 6/4885HTT 4732/4885 |
| US-20100063583-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ALOX15B, ALOX15, ALOX12 | EPHX2 6/4885HTT 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.